
Opinion|Videos|July 1, 2026
Prophylactic Anticoagulation With Amivantamab Plus Lazertinib in EGFR+ NSCLC
Author(s)Misako Nagasaka, MD, PhD
Misako Nagasaka, MD, PhD, explains the use of prophylactic anticoagulation for preventing venous thromboembolism (VTE) when administering amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. The prophylactic anticoagulation is particularly recommended for the first 4 months of treatment, when the risk of VTE is highest.
Advertisement
Episodes in this series

Misako Nagasaka, MD, PhD, explains the use of prophylactic anticoagulation for preventing venous thromboembolism (VTE) when administering amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. The prophylactic anticoagulation is particularly recommended for the first 4 months of treatment, when the risk of VTE is highest.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Orca-T Gains FDA Approval in Matched Donor Transplants
2
Q3 2026 Oncology Outlook: Key FDA Decisions to Watch
3
Factors Affecting First-Line ICI Choice in HER2-Negative Gastric Cancer
4
Experts Weigh Fixed-Duration Approaches in Frontline CLL
5








































